Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 15, Number 10—October 2009

Nontuberculous Mycobacteria Infections and Anti–Tumor Necrosis Factor-α Therapy

Kevin L. WinthropComments to Author , Eric Chang, Shellie Yamashita, Michael F. Iademarco, and Philip A. LoBue
Author affiliations: Oregon Health and Sciences University, Portland, Oregon, USA (K.L. Winthrop, E. Chang, S. Yamashita); US Public Health Service, Washington, DC, USA (M.F. Iademarco); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (P.A. LoBue)

Main Article

Table 3

Characteristics of 105 pulmonary and nonpulmonary anti–TNF-α therapy–associated cases of NTM disease, US Food and Drug Administration MedWatch database, 1999–2006*

Characteristic Pulmonary (n = 59), no. (%) Extrapulmonary (n = 46), no. (%)
Mycobacterium avium 43 (73) 9 (20)†
RGM 6 (10) 15 (33)†
Age, y 61 63
Female patient 41 (73) 25 (54)†
Rheumatoid arthritis 48 (81) 25 (54)†
Infliximab 40 (68) 33 (72)
Etanercept 13 (22) 12 (26)

*TNF-α, tumor necrosis factor-α; NTM, nontuberculous mycobacteria; RGM, rapidly growing mycobacteria.
†p<0.05 for comparison of pulmonary disease and extrapulmonary disease.

Main Article

Page created: December 08, 2010
Page updated: December 08, 2010
Page reviewed: December 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.